KabaFusion

2022年9月23日

消息人士告訴Axios, Novo Holdings已同意收購普利茲克私人資本(Pritzker Private Capital)旗下的KabaFusion，這是一家專門從事靜脈注射免疫球蛋白(IVIG)的家庭輸液公司。重要原因:家庭輸液市場高度分散，這為創建另一個更類似於OptumRx和Option Care Health這兩大公司的大型多元化平台整合提供了機會。新近獲得支持的KabaFusion可能是這一目標的起點。細節:該交易的確切價格無法證實，但估值可能超過10億美元。此前有消息稱，2022年市場銷售的EBITDA為5700萬美元，或2022年形式的EBITDA接近7500萬美元，兩名消息人士表示，該交易的市盈率約為19 -20倍。消息人士稱，Houlihan Lokey是該公司的顧問。KabaFusion獲得了44個州的患者服務許可，本月早些時候，通過收購Coram的資產，KabaFusion在25個州的專業藥房業務幾乎翻了一番。回憶一下:有消息人士此前告訴Axios，普利茲克於2019年以大約2.5億美元的價格收購了KabaFusion，這是一筆十幾倍的交易。他們說，隨後在2020年收購了Lincare的輸液藥房係列，使營收增加了約1億美元。背景:總部位於丹麥的Novo公司正通過其主要投資部門在美國醫療保健和生命科學領域迅速成名，KabaFusion將是該公司今年第三個此類投資項目。 The Principal Investments team put feet on the ground in Boston in 2021, with those efforts led by former Temasek health care investor Abhijeet Lele, who joined in late 2020 alongside ex-CVC Capital investor Jonathan Levy. KabaFusion would follow the acquisitions of Ritedose and Medical Knowledge Group in January 2022; and Altasciences and Availity in March and July 2021, respectively. State of play: The IVIG market is growing , and other PE-backed infusion therapy providers offer this therapy including H.I.G. Capital's Soleo Health, Linden Capital's Vital Care, and Waud Capital Partners' PromptCare. ???? Our thought bubble: The issue of drug concentration is top of mind for investors who spoke with Axios, which is why we suspect Novo is not only a believer in IVIG's underlying trends but has a bigger, broader vision around home infusion. Novo declined to comment, while Pritzker and Houlihan did not return requests for comment. Claire Rychlewski contributed reporting.